文献速递外周动脉疾病

以血栓强度预测外周动脉疾病血栓形成的研究

The Use of Clot Strength as a Predictor of Thrombosis in Peripheral Artery Disease.
PubMed 文献 · Ann Vasc Surg · 2024-07-26

这项前瞻性观察研究纳入158例60岁以上接受血运重建的外周动脉疾病患者,2021至2023年随访1年,用血栓弹力图血小板图(TEG-PM)评估凝血 profile。28例(17.7%)发生血栓事件,血栓组MAADP、MAFibrin、MAThrombin均显著高于无血栓组。ROC分析显示MAADP>42 mm预测血栓风险的最佳截断值,敏感度82%、特异度50%。

要点

  • 血栓组MAADP 50.2 vs 无血栓组40.0(P<0.05),提示血栓强度更高。
  • MAADP>42 mm预测血栓风险的敏感度82%、特异度50%。
  • 血栓强度增加可预测30天内的血栓/狭窄事件。

核心结论

  • 血栓强度增加可预测30天内的血栓/狭窄事件,MAADP>42 mm可能作为调整抗血小板用药的替代方法,可能降低血栓风险。

研究设计与样本

  • 前瞻性观察研究,纳入2021至2023年60岁以上接受血运重建的外周动脉疾病患者,临床随访1年,于1、3、6、9个月行TEG-PM检测。
  • 共分析158例患者,按是否发生血栓/狭窄事件分组,采用卡方检验、非配对t检验及ROC分析。

主要发现

  • 158例中28例(17.7%)发生血栓事件。
  • 血栓组MAADP为50.2 vs 无血栓组40.0(P<0.05),血栓组更高。
  • 血栓组MAFibrin为18.19 vs 无血栓组14.64(P<0.05),血栓组更高。
  • 血栓组MAThrombin为63.8 vs 无血栓组58.5(P<0.05),血栓组更高。
  • ROC分析显示MAADP>42 mm预测血栓风险最佳,敏感度82%、特异度50%(P<0.05)。

关键数值与推荐

  • MAADP>42 mm为预测较高血栓风险的最佳截断值,敏感度82%、特异度50%(P<0.05)。

临床怎么用

  • 作者认为MAADP>42 mm的截断值可能作为调整抗血小板用药的替代方法,可能降低血栓风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Graft/stent thrombosis is the leading cause of amputation in patients over 60, and while dual antiplatelet therapy is the standard of care, there is a significant variability in platelet response and limited guidance on measuring effectiveness. Thromboelastography with platelet mapping (TEG-PM) can objectively detail an individual's coagulation profile, namely the strength of the clot and its response to antiplatelet medication. Although TEG-PM has been used for predicting postoperative bleeding and assessing platelet dysfunction in traumatic brain injury, its application in thrombosis diseases such as peripheral artery disease remains unexplored. The aim of this observational study was to determine if objective measures of clot strength could predict a high clinical risk of thrombosis. METHODS: Patients >60 years with peripheral artery disease undergoing revascularization were prospectively evaluated from 2021 to 2023. They were clinically followed for 1 year to detect any thrombotic events. TEG-PM was used to objectively evaluate coagulation profiles in patients at 1, 3, 6, and 9 months. These follow-up periods were chosen based on studies showing that 1-3 month intervals in the first year after lower extremity revascularization optimize therapy and risk control. The TEG-PM data preceding a thrombotic/stenotic event in patients with thrombosis was compared to the last known well TEG-PM event in those without a thrombotic/stenotic event. We stratified the groups based on the occurrence of thrombosis/stenotic events. Descriptive statistics were applied to characterize each group and a chi-square test was conducted to assess the variance between both groups. An unpaired t-test was run to identify differences in platelet function. Receiver operating characteristic analysis was performed to determine the optimal TEG-PM cutoff for predicting a higher risk of thrombosis. RESULTS: One hundred and fifty-eight patients were analyzed, from whom 28 (17.7%) experienced a thrombotic event. The thrombosis cohort exhibited significantly greater MAADP, MAFibrin, and MAThrombin [50.2 vs. 40.0, P < 0.05], [18.19 vs. 14.64, P < 0.05], and [63.8 vs. 58.5, P < 0.05], respectively, indicative of greater clot strength. By receiver operating characteristic analysis, the optimal predictor cut-off for MAADP, indicating a higher risk of thrombosis, was >42 mm [P < 0.05] with 82% sensitivity and 50% specificity. CONCLUSIONS: An increase in clot strength was found to be predictive of thrombosis/stenosis within 30 days. Using a MAADP cut-off greater than 42 mm might serve as an alternative approach to tailor the use of antiplatelet medication, potentially reducing the risk of thrombosis.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Suarez Ferreira S, Agrawal A, Lee I, et al. The Use of Clot Strength as a Predictor of Thrombosis in Peripheral Artery Disease. Ann Vasc Surg. 2024. PMID: 39069123. doi:10.1016/j.avsg.2024.06.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。